Zhang Guangzhao, Hu Yanlei, Yuan Wuying, Qiu Hongli, Yu Haifeng, Du Jiahui
Department of Minimally Invasive Surgery, Henan Chest Hospital, Zhengzhou, Henan 450003, People's Republic of China.
Department of Cardiovascular Surgery, Fuwai Central China Cardiovascular Hospital, Zhengzhou, Henan 451464, People's Republic of China.
Onco Targets Ther. 2020 Oct 12;13:10257-10266. doi: 10.2147/OTT.S252795. eCollection 2020.
Non-small cell lung cancer (NSCLC) is a heterogeneous tumor that accounts for approximately 85% of all lung cancer cases worldwide. microRNAs (miRNAs) are believed to play an important role in regulating a variety of biological processes, including immunity and cancer. We investigated the effect of miR-519d-3p on the mitigation of NSCLC in vitro and in vivo.
RT-PCR or immunohistochemical assays were used to assess the expression of miR-519d-3p. Colony formation, flow cytometry, and transwell assay were respectively used to detect proliferation, apoptosis, and invasion of A549 and NCI-H661 cell lines. Luciferase reporter assay was used to verify targeting the relationship between mir-519d-3p and VEGFA. Western blot was used to examine the expression of Ki67, caspase-3, E-cadherin, N-cadherin, VEGF, P38, and PI3K/AKT. Animal models were established by BABL/c mice to research the effect of mir-519d-3p overexpression in vivo.
In vitro, miR-519d-3p overexpression inhibited A549 and NCI-H661 cells proliferation, invasion, and also promoted apoptosis. In addition, miR-519d-3p overexpression downregulated VEGFA expression and decreased the P38 and PI3K/AKT phosphorylation level. In vivo, miR-519d-3p overexpression significantly restrained tumor volume (2087±265 mm vs 599±135 mm, < 0.05) and tumor weight (0.45±0.08 g vs 0.13±0.06 g, <0.05) compared with the control group. Overexpression of miR-519d-3p downregulated levels of Ki67 and N-cadherin significantly.
The data indicated that miR-519d-3p could be a novel therapy or adjuvant against NSCLC.
非小细胞肺癌(NSCLC)是一种异质性肿瘤,约占全球所有肺癌病例的85%。微小RNA(miRNA)被认为在调节包括免疫和癌症在内的多种生物学过程中发挥重要作用。我们研究了miR-519d-3p在体外和体内对NSCLC缓解的影响。
采用RT-PCR或免疫组化分析评估miR-519d-3p的表达。分别采用集落形成、流式细胞术和Transwell实验检测A549和NCI-H661细胞系的增殖、凋亡和侵袭。采用荧光素酶报告基因实验验证mir-519d-3p与VEGFA之间的靶向关系。采用蛋白质免疫印迹法检测Ki67、caspase-3、E-钙黏蛋白、N-钙黏蛋白、VEGF、P38和PI3K/AKT的表达。通过BABL/c小鼠建立动物模型,研究mir-519d-3p过表达在体内的作用。
在体外,miR-519d-3p过表达抑制A549和NCI-H661细胞的增殖、侵袭,并促进细胞凋亡。此外,miR-519d-3p过表达下调VEGFA表达,降低P38和PI3K/AKT磷酸化水平。在体内,与对照组相比,miR-519d-3p过表达显著抑制肿瘤体积(2087±265 mm对599±135 mm,<0.05)和肿瘤重量(0.45±0.08 g对0.13±0.06 g,<0.05)。miR-519d-3p过表达显著下调Ki67和N-钙黏蛋白水平。
数据表明,miR-519d-3p可能是一种针对NSCLC的新型治疗方法或辅助治疗手段。